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Introduction: This study was designed to develop a both sensitive
and efficient algorithm for detection of lymph node micrometastases
and to determine its prognostic impact in patients with early stage
non-small cell lung cancer (NSCLC).
Methods: One hundred seventy patients with NSCLC p stage I and
II were included in this study, of which n 5299 lymph nodes were
obtained and submitted to histopathologic analysis. From each patient,
a median number of 31 lymph nodes was received (N-1 position:
median n 16; N-2 position: median n 15). Immunohistochemistry
was performed to detect micrometastases unobvious by conventional
microscopy using antibodies against cytokeratins (CK) (pan-CK: KL-1,
CK 5/6, CK 7) and the epithelial marker Ber-EP4.
Results: In 82 patients (48.2%), micrometastases were revealed in
immunohistochemistry staining. KL-1 detected micrometastases in 201
(99.5%) of 202 positive lymph nodes. Subsequently, this resulted in an
upstaging in 39 patients (20.5%). Detection of micrometastases in
otherwise tumor-free N2-lymph nodes had a significant prognostic
impact (mean disease-free survival 21.4 versus 45.3 months, p 
0.022), affecting 4.7% of patients. Survival differences between patients
who were upstaged into stage II (N0N1) and those remaining in stage
I were not statistically significant (p  0.537).
Conclusion: Extended workup of N2-lymph nodes using one broad-
spectrum keratin marker in otherwise N2-negative lymph nodes may
represent a both efficient and sensitive approach to the identification
of micrometastases in dissected lymph nodes of patients with early
stage NSCLC.
Key Words: Micrometastases, Lymph node, Lung cancer, Immu-
nohistochemistry, Prognostic impact.
(J Thorac Oncol. 2010;5: 1206–1212)
Complete surgical resection remains the current standardtherapy for operable patients with non-small cell lung
cancer (NSCLC) in the stages I or II. However, there is a
strong rationale for an additional adjuvant systemic therapy
even in patients with early stage disease because distant
relapse continues to be the dominant form of relapse after
curative surgical resection of NSCLC.1,2 Treating all patients
after (or before) complete resection of NSCLC with adjuvant
chemotherapy will clearly not benefit each one. Patients
surviving 5 years after surgery without relapse, which ac-
counts for 60% of patients with stage I NSCLC would not
have done any better by having received additional chemo-
therapy.3 Thus, the identification of those patients with a poor
prognosis that may benefit from additional therapy after
surgery continues to be of high importance.
We hypothesized that occult micrometastases in lymph
nodes may be associated with poor prognosis after complete
resection in patients with early stage NSCLC. Micrometastasis
as defined by Union International contre le Cancer (UICC)/The
American Joint Committee (AJCC)4,5 is a small tumor deposit
0.2 to 2m in diameter, usually detected by routine hematoxylin
and eosin (HE) staining, and typically mitoses and invasion are
seen.6 In contrast, isolated tumor cells (ITC) are small clumps of
tumor cells, typically without mitoses or vascular or lymphatic
invasion within nodes (or distant sites). Micrometastases can be
detected by standard histopathology, albeit with lower sensitiv-
ity. Therefore, to date, immunohistochemistry (IHC) remains the
gold standard for the detection of micrometastases. Although a
prognostic impact of occult lymph node micrometastases in lung
cancer has been discussed by many authors, IHC for detection of
lymph node micrometastases has not been implemented in
routine diagnostic procedures mainly due to high costs. This
study was designed to develop both a sensitive and inexpensive
algorithm of IHC for the detection of occult lymph node micro-
metastases and to determine their prognostic impact in a large
number of patients with early stage NSCLC.
PATIENTS AND METHODS
Patients
A total number of 170 completely resected patients
with NSCLC with pathologic stages I and II (February 2003
until August 2005) was included in this trial. During preop-
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erative staging, enlarged (1 cm) mediastinal lymph nodes
on computed tomography (CT) scan were diagnosed in 19
patients and resulted in clinical N2 classifications; n  16 of
these patients had single station minimal cN2 disease and the
interdisciplinary tumor board decided on primary surgery. In
n  3 patients with multilevel cN2, mediastinoscopy was
performed and revealed negative mediastinal nodes. Positron
emission tomography scan was not routinely available during
the study period and was performed in none of the patients.
No induction treatments were performed. All patients under-
went primary surgery and finally turned out to be N2 negative
by pathologic staging after complete lymph node dissection.
The standard surgical procedure was anterolateral thoracot-
omy, entering in the fourth or fifth intercostal space. Radical
mediastinal and hilar lymphadenectomy were performed con-
currently with all procedures, including four compartments in
the right-sided thoracotomy (paratracheal, infracarinal, infe-
rior mediastinal, and hilar) and four compartments in the
left-sided thoracotomy (aortic, infracarinal, inferior medias-
tinal, and hilar).7,8 Standard postoperative histopathologic
investigation (HE staining) was performed according to the
sixth edition of the TNM classification of the International
Union Against Cancer.9 Each participant in this study was
informed and written consent to participation was given
before entering the trial. The study was formally approved by
the Ethics Committee of the University of Heidelberg (No:
270/2001).
Tissue Preparation and Standard
Histopathologic Analysis
For routine histopathologic analysis, lymph nodes were
embedded in paraffin and further processed for routine HE
staining. The standard histopathologic analysis included
one section through the middle in those lymph nodes in which
the shortest axis fell short of 5 mm, and two sections in those
lymph nodes in which the shortest axis exceeded 5 mm.
Immunohistochemical Analysis
For IHC of the lymph nodes, four additional sections of 2
m thickness with a distance of 150 m in between were
performed. The slides were deparaffinized and pretreated in an
antigen retrieval buffer (DAKO, Glostrup, Denmark) to block
unspecific bindings. Subsequent steps were performed in an
immunostaining device (DAKO, Techmate 500 plus). The im-
munostaining protocol was based on the avidin-biotin-peroxi-
dase principle, which used amino-9-ethylcarbazole as chromo-
gen, as well as hematoxylin for the counter stain. The tissue
sections were covered with glycerine gelatin. After each incu-
bation period, the capillary slides were rinsed and dried with
blotting pads. Immunohistochemical staining was performed
with antibodies raised against pan-cytokeratins (CK) (KL-1);
1:50 (Immunotech, Marseille, France), CK 5/6; 1:100 (DAKO,
Glostrup, Denmark), CK 7; 1:100 (DAKO, Glostrup, Denmark),
and BerEp-4; 1:200 (DAKO, Glostrup, Denmark). For negative
controls, the primary antibodies were omitted. As positive con-
trols, normal colon mucosa was used for Ber-EP4 and known
positive tumor samples of NSCLC were used for CK 7-Ab, CK
5/6-Ab, and KL-1. In the IHC analysis of the lymph nodes, small
tumor deposits (as defined by the UICC/AJCC) were defined as
micrometastasis; solitary tumor cells or clump of cells without
mitoses or vascular invasion were not defined as micrometastases.
Follow-Up
Eleven of the 170 patients received postoperative adjuvant
chemotherapy (stage I: n  4), stage II: n  7). None of the
patients received pre- or postoperative radiotherapy. All patients
were followed-up (including physical examination, chest roent-
genogram, chest CT, and abdominal ultrasonography) every 3
months over the first 2 years and in 6 months intervals thereafter.
End point of follow-up was disease-free survival (DFS).
Statistical Analysis
The results were evaluated by SPSS (Statistical Pack-
age for Social Sciences) Windows 15.0 software for statisti-
cal analysis. The Wilcoxon signed rank test was used for
comparing qualitative data. The analysis of the DFS time was
performed by Kaplan-Meier analysis. The results were eval-
uated with a 95% confidence interval. A p value 0.05 was
regarded as statistically significant.
RESULTS
One hundred seventy patients with a mean age of 65.4
years were included in this study. A synopsis of the clinical
data and the histopathologic classification of the tumors is
shown in Table 1. A total of 5299 lymph nodes underwent
histopathologic analysis (N-1 position: n  2722; N-2 posi-
tion: n  2577); a median number of 31  13 lymph nodes
was obtained from each patient (N-1 position: median 16 
9; N-2 position: median 15  8). Subsequently, a total of
21,196 histologic sections were analyzed by four different
immunohistochemical stainings.
By immunostaining, micrometastases were detected in
375 sections corresponding to a total of 202 lymph nodes.
The pan-CK antibody KL-1 detected micrometastases in 201
lymph nodes (99.5%) and CK7-Ab in 107 lymph nodes
(52.9%). The CK5/6 antibody was less sensitive and detected
micrometastases only in 15 lymph nodes (7.4%). The epithe-
lial marker BerEp4 revealed micrometastases in 52 lymph
nodes (25.7%). KL-1 failed to detect micrometastases in only
one patient in which the presence of the single CK marker
CK7 solely proofed micrometastases (Table 2).
Lymph nodes of 82 patients (48.2%) revealed microme-
tastases by immunohistochemical staining. Subsequently, 39
patients (20.5%) were immunohistochemically upstaged.
Among patients with N0 status in standard histopathology, 35
patients (29.6%) were immunohistochemically upstaged
(N03N1: n  31; N03N2: n  4). In addition, four patients
initially classified as pN1 in standard histopathology (8.4%)
were immunohistochemically upstaged due to the detection of
micrometastases in N2-lymph nodes. In 43 patients presenting
with metastases in N1 lymph nodes by HE staining, additional
tumor cell clusters defined as micrometastases were found by
IHC. Of course, this finding did not result in an upstaging of the
tumor disease. The reclassification of the patients according to
the lymph node status after IHC is shown in Table 3. On the
basis of the clinical staging, none of the CT-based clinical
N2-positive patients had postoperative pathologic N2 disease by
conventional workup. However, in mediastinal nodes of 2 of
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these 19 patients, micrometastases were detected by immuno-
histochemical staining.
Tumor size did not correlate with upstaging of patients
according to micrometastases detected by immunohistochem-
istry. Mean tumor size in patients with unchanged stages (n
131) was 4.3 cm, mean tumor size in patients upstaged from
pN0 to pN1 was 3.7 cm, and mean tumor size in patients
upstaged from pN0/pN1 to pN2 (n 8) was 4.25 cm (Table 4).
Information on survival was obtained from all subjects.
The median follow-up time was 37.1 months. In total, 51 of the
TABLE 3. Lymph Node Status of Patients According to
Routine Histopathologic Analysis (HE Staining) and After
Extended Workup Including Further Serial Sectioning and
Immunohistochemistry
Patients Lymph
Node Status
HE Staining,
n (%)
Extended Workup,
n (%)
N0 123 (72.4) 88 (51.8)
N1 47 (27.6) 74 (43.5)
N2 0 (0) 8 (4.7)
Total 170 (100) 170 (100)
HE, hematoxylin and eosin.
TABLE 4. Tumor Size, T Status, N Status, Clinical Stage,
Pathologic Stage, and Histology of Patients with IHC-Positive
N2 Disease (n  8)
T Size (cm) pT pN c Stage p Stage Histo
5.5 2 0 IB IB AD
3.3 2 0 IB IB AD
3.5 2 0 IB IB AD
3.0 2 0 IB IB AD
8.0 2 1 IIIA IIB SCC
4.5 2 1 IIIB IIB SCC
4.0 2 1 IB IIB AD
2.2 1 1 IA IIA AD
SC, squamous cell carcinoma; AD, adenocarcinoma; IHC, immunohistochemistry.
TABLE 5. Disease-Free Survival After Extended Workup
and Restaging
Lymph Node
Status After
Extended
Workup
Patients,
n (%)
Mean
Survival
(mo)
Standard
Deviation
(mo)
95% Confidence
Interval
Lower
Range
Upper
Range
pN0 - pN0 88 (51.8) 45.35 2.43 40.58 50.11
pN0 - pN1 31 (18.2) 44.25 2.77 38.83 49.67
pN1 - pN1 43 (25.4) 43.32 3.46 36.53 50.11
pN0/1 - pN2 8 (4.6) 21.36 3.57 14.37 28.34
TABLE 6. Overall Survival After Extended Workup and
Restaging
Lymph Node
Status After
Extended
Workup
Patients,
n (%)
Overall
Survival
(mo)
Standard
Deviation
(mo)
95% Confidence
Interval
Lower
Range
Upper
Range
pN0 - pN0 88 (51.8) 51.3 1.9 47.5 55.0
pN0 - pN1 31 (18.2) 52.5 2.5 47.6 57.4
pN1 - pN1 43 (25.4) 46.8 3.3 40.4 53.1
pN0/1 - pN2 8 (4.6) 28.6 4.6 19.7 37.5
TABLE 1. Patients Characteristics, Histologic Differentiation
and Stage of Tumors in Standard HE Staining
Number of Patients (n)
Gender
Male 121 (71.2)
Female 49 (28.8)
Tumor type
Squamous cell carcinoma 80 (47.1)
Adenocarcinoma 74 (43.5)
Others 16 (9.4)
P stage
Stage I 123 (72.4)
Stage II 47 (27.6)
pT status
pT1 23 (13.5)
pT2 147 (86.5)
pN status
pN0 123 (72.6)
pN1 47 (27.6)
Clinical stage
I 112 (65.9)
II 23 (13.5)
IIIa 24 (14.1)
IIIb 8 (4.7)
IV 1 (0.6)
Not specified 2 (1.2)
Clinical T status
1 28 (16.5)
2 121 (71.2)
3 12 (7.1)
4 7 (4.1)
Clinical N status
cN0 119 (70.0)
cN1 30 (17.6)
cN2 19 (12.2)
Not specified 2 (1.2)
Staging according to 6th edition. The values given in the parentheses represent percentage.
HE, hematoxylin and eosin.
TABLE 2. Immunohistochemical Detection (KL-1, CK 7, CK
5/6 and BerEp4) of Micrometastasis in Lymph Nodes of
NSCLC Depending on Histological Subtypes
Lymph
Nodes (n)
Lymph Nodes (n) with
Micrometastases
Detected by IHC
KL-1 CK 7 CK 5/6 BerEP4
Adenocarcinoma (n) 2282 81 59 4 28
Squamous cell
carcinoma (n)
2515 108 40 11 19
Others (n) 502 12 8 0 5
Total IHC (n) 5299 201 107 15 52
CK, cytokeratin; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry.
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170 patients had a recurrence of their cancer that occurred
locally in the ipsilateral chest (n  9), in the contralateral lung
(n 8), as distant metastases (n 19), or as combined local
distant recurrences (n  6). In n  9 patients, the site of the
recurrences was not specified. One of the 51 patients with
recurrences had postoperative adjuvant chemotherapy. The
mean DFS after adaptation of the tumor stage was 45.3 months
(3-year DFS 72.4%) in those patients remaining in stage I (n 
88). Patients with the positive finding of micrometastases in
N1-lymph nodes who were upstaged into stage II (n  31) had
a mean DFS of 44.3 months (3-year DFS 70.2%). Patients
remaining in stage II but with additionally detected microme-
tastases in N1-lymph nodes (n  43) had a mean DFS of 43.3
months (3-year DFS 65.1%). Patients with micrometastases in
N2-lymph nodes that led to an upstaging into stage IIIA (n 8)
had a shorter mean DFS of 21.4 months (3-year DFS 0%). This
difference was statistically significant (p  0.022). Differences
in survival between patients who were upstaged from stage I into
stage II and those who remained in stage I were not statistically
significant (p  0.537). A synopsis of the follow-up data is
shown in Tables 5 and 6, the respective survival curves are
shown in Figures 1–3.
DISCUSSION
In our series, serial sectioning and the application of
IHC detected additional lymph node micrometastases in
FIGURE 1. Disease-free survival of patients
staged by standard histopathologic workup (stage
I: blue line, stage II: green line).
FIGURE 2. Disease-free survival (DFS) of patients
restaged (upstaged) according to detection of
nodal micrometastases after extended workup:
patients with micrometastases in N2-lymph nodes
(red line) had a statistically significant (p  0.022)
shorter mean DFS as compared with N0/1 pa-
tients. DFS of patients with negative nodes (blue
line) and of patients with micrometastases in N1-
lymph nodes (green line) was not statistically sig-
nificant (p  0.537) different.
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48.2% of the patients (n  82) with NSCLC stage I and II.
Literature reports a prevalence of additionally detected mi-
crometastases of 10.4% up to 70.5% depending on the tumor
characteristics, stage, the employed standard histopathologic,
and immunohistochemical techniques as well as the respec-
tive definition of micrometastases.10–14 Although a clear
definition for micrometastases exists, there is a mixture of
different terminologies and the term micrometastasis is used
for “true micrometastases,” as well as for tumor cell clusters
and for ITC.15–21 In this study, micrometastases were defined
according to the UICC/AJCC1,2 as a small tumor deposit 0.2
to 2 m in diameter, usually detected by routine HE staining,
and typically mitoses and invasion are seen.3 Isolated posi-
tively stained tumor cells (ITC) that are small clumps of
tumor cells, typically without mitoses or vascular or lym-
phatic invasion within nodes were not counted as microme-
tastases. Likewise, immunohistochemically positive epithe-
lial cells that did not fulfill histologic and cytomorphologic
criteria of cancer cells were identified as heterotopic epithe-
lial inclusions in lymph nodes.
In this study, three different keratin markers (KL-1
[broad-spectrum keratin, composed of a total of 11 keratins],
7, 5/6) and one other epithelial marker (BerEp4) were applied
for IHC.22–24 Tumors derived from epithelial cells typically
retain the keratin profile of the cell type of origin.13,25 Kera-
tins are not specific to tumor cells but are also present in
normal and heterotopic epithelial cells; thus, a positive reac-
tion may be seen in any type of epithelial cell in lymph nodes.
False-positive findings, however, can be neglected in our
study because positive cells were only counted as microme-
tastasis when histomorphologically reconfirmed.
KL-1 is a broad mixture of monoclonal antibodies that
reacts with almost all intermediate filaments of epithelial cells
without showing cross-reactivity with other intermediate fil-
aments. CK filaments are a constant feature of all carcinomas,
including all types of lung cancers, regardless of their degree
of differentiation.12 KL-1 detects the keratins 2, 5, 6, 8, 10, 18,
and 19. Therefore, the antibody binds to adenocarcinomas as
well as squamous cell carcinomas. KL-1 is not the only marker
being used for detection of metastasis in lymph nodes of patients
with NSCLC. Aside from AE1/AE314 however, it has been used
frequently for detection of lymph node micrometastasis also in
e.g., patients with breast carcinoma26 or patients with colonic
cancer.27 Other studies were using monoclonal antibodies to
keratins (28) or BerEP410 to detect nodal micrometastasis in
lymph nodes in lung cancer with similar results.
In our study, the broad-spectrum keratin marker, KL-1,
was by far the most sensitive single marker, detecting 99.5%
of nodal micrometastases. The single marker keratin 7 de-
tected one additional micrometastasis, which for unknown
reasons KL-1 failed to stain; but this did not result in
upstaging. Compared with KL-1, no additional micrometas-
tases were detected by keratin 5/6 and BerEp4 immunostain-
ing. Thus—according to our results—with the application of
a single marker for IHC, the parallel use of other markers can
be suspended. In a setting similar to ours in colon cancer,
KL-1 was the most suitable antibody within a series of four
different antibodies for the diagnosis of micrometastases.27 In
this and in our study, the combined effects of IHC and further
serial sectioning resulted in significantly improved detection
rates of nodal micrometastases. However, because microme-
tastases in principle are detectable with routine HE staining,
the additional sectioning alone may result in increased detec-
tion rates among experienced reviewers.
The prognostic impact of micrometastases is still de-
bated; several authors report on a shorter survival when
micrometastases are present, others fail to demonstrate a
negative prognostic impact of micrometastases.28–31 How-
ever, the data are difficult to compare because the study
designs varied with regard to tumor stage, histology, extent of
FIGURE 3. Overall survival (OS) of patients re-
staged (upstaged) according to detection of nodal
micrometastases after extended workup: patients
with micrometastases in N2-lymph nodes (red
line) had a statistically significant (p  0.001)
shorter mean OS as compared to N0 patients. OS
of patients with negative nodes (blue line) and of
patients with micrometastases in N1-lymph nodes
(green line) was not statistically significant
(p  0.191) different.
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lymph node dissection, standards in routine histopathology,
and immunohistochemical techniques as well as in the clas-
sification of micrometastases in distinction to ITC. Further-
more, many authors do not distinguish between anatomic
lymph node positions and the subsequent upstaging of the
patients.19,32 In our series, only the detection of nodal micro-
metastases in N2-lymph nodes (resulting in an upstaging into
stage IIIA) had a significant prognostic impact. This however,
affects only a small proportion of patients (4.7%). DFS of
patients with newly or additionally detected micrometastases
in the N1-lymph node positions was not significantly differ-
ent to patients with N0-status (Figure 2; Table 4). None of the
patients with micrometastases in N2-lymph nodes had a DFS
beyond 30 months, whereas 70% of the pN0/N1 patients
were clinically disease free at that time. Corresponding to our
results, Osaki et al. and Hashimoto et al.28,33 also revealed a
significantly shorter survival of patients with micrometastases
in the N2-lymph node positions. DFS rates in our series were
not significantly different between stage I and II. This may be
due in part to the high percentage of T2 tumors (86.5%) and
the lack of statistical power due to the small number of
patients studied (stage I: n  123; stage II: n  47). In
patients who were immunohistochemically upstaged to stage
IIIA median overall survival dropped to 28.6 months. How-
ever, this is based on data from only nine patients. Consid-
ering this small number of patients, these survival rates are in
the ranges reported from other series.3
The results of our study may suggest a modification in
the workup of lymph nodes in NSCLC. For the detection of
micrometastases through routine serial sectioning with IHC,
extensive labor and costs required for examining up to 40
lymph nodes, removed in a typical lung cancer resection,
remain a limiting factor for clinical acceptance. Thus, a more
focused approach to the detection of occult nodal microme-
tastasis is warranted. In conclusion of our study, we suggest
a pragmatic algorithm (Figure 4). By limiting immunohisto-
chemical analysis to the negative N2-lymph nodes in standard
HE staining and solely applying the broad-spectrum keratin
marker KL-1, the additional expenses are greatly limited.
Based on the data of this study with a median number of 15
dissected N2-lymph nodes, 5 additional immunohistochemi-
cally stained slides are required per patient.
FIGURE 4. Suggested algorithm for an extended
histopathologic workup aimed at detection of
nodal micrometastases in resected stage I/II
NSCLC. NSCLC, non-small cell lung cancer.
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To date, IHC still represents the gold standard in the
detection of micrometastases. However, quantitative reverse
transcription-polymerase chain reaction potentially may become
the future standard for the detection of micrometastases.33–36
Long-term follow-up data with this technique, however, are still
missing—further investigations are required and will have to
measure up to the data based on IHC. Moreover, as demon-
strated in our study, heterotopic cell nests and ITC in lymph
nodes may be snares for polymerase chain reaction-guided
lymph node analyses that may cause false-positive results.
CONCLUSION
Serial sectioning and the application of IHC detected
additional micrometastases in dissected lymph nodes in 48.2%
of patients with NSCLC stage I and II. However, only the
detection of nodal micrometastases in N2-lymph nodes had a
negative impact on survival, affecting only a small proportion of
patients (4.7%). Extended workup of N2-lymph nodes using one
broad-spectrum keratin marker in otherwise N2-negative lymph
nodes may represent a both efficient and sensitive approach to
the identification of this subgroup of patients.
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